Royal Bank of Canada
NRIX icon

Royal Bank of Canada’s Nurix Therapeutics NRIX Stock Holding History

Royal Bank of Canada’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58K Sell
3,687
-7,155
-66% -$119K ﹤0.01% 5417
2025
Q4 		$206K Buy
10,842
+1,623
+18% +$23.3K ﹤0.01% 4738
2025
Q3 		$85K Sell
9,219
-104,014
-92% -$1.08M ﹤0.01% 5593
2025
Q2 		$1.29M Buy
113,233
+106,418
+1,562% +$1.15M ﹤0.01% 3676
2025
Q1 		$81K Sell
6,815
-10,938
-62% -$183K ﹤0.01% 5341
2024
Q4 		$334K Sell
17,753
-25,495
-59% -$584K ﹤0.01% 4401
2024
Q3 		$973K Buy
43,248
+37,458
+647% +$849K ﹤0.01% 3574
2024
Q2 		$121K Buy
5,790
+4,626
+397% +$72K ﹤0.01% 5150
2024
Q1 		$17K Sell
1,164
-13,759
-92% -$148K ﹤0.01% 5983
2023
Q4 		$154K Buy
14,923
+6,816
+84% +$46.7K ﹤0.01% 5310
2023
Q3 		$64K Buy
8,107
+2,303
+40% +$21K ﹤0.01% 5639
2023
Q2 		$58K Buy
5,804
+3,078
+113% +$31.4K ﹤0.01% 5701
2023
Q1 		$24K Sell
2,726
-4,357
-62% -$45.4K ﹤0.01% 5962
2022
Q4 		$77K Buy
7,083
+6,310
+816% +$76.1K ﹤0.01% 5634
2022
Q3 		$10K Buy
773
+420
+119% +$6.65K ﹤0.01% 6428
2022
Q2 		$4K Sell
353
-1,674
-83% -$19K ﹤0.01% 6739
2022
Q1 		$28K Sell
2,027
-5,068
-71% -$90K ﹤0.01% 6423
2021
Q4 		$205K Buy
7,095
+6,786
+2,196% +$206K ﹤0.01% 5313
2021
Q3 		$9K Buy
309
+163
+112% +$5.03K ﹤0.01% 7004
2021
Q2 		$4K Sell
146
-2,044
-93% -$60K ﹤0.01% 7124
2021
Q1 		$68K Buy
2,190
+1,785
+441% +$67.5K ﹤0.01% 5692
2020
Q4 		$13K Buy
405
+305
+305% +$10.1K ﹤0.01% 6270
2020
Q3 		$3K Buy
+100
New +$2.52K ﹤0.01% 6254

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Royal Bank of Canada's NRIX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Nurix Therapeutics (NRIX) stake by 66% in Q1 2026, selling an estimated $119K and leaving 3,687 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #5417.

Royal Bank of Canada first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.29M in Q2 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Royal Bank of Canada held 3,687 shares of Nurix Therapeutics worth $58K as of Q1 2026.
  • Royal Bank of Canada sold 7,155 Nurix Therapeutics shares in Q1 2026, an estimated $119K.
  • Nurix Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5417 holding.
  • Royal Bank of Canada first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Royal Bank of Canada's Nurix Therapeutics position peaked at $1.29M in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.